Status:
RECRUITING
Middle Meningeal Artery Embolization for Chronic Subdural Hematomas (STORMM)
Lead Sponsor:
University Hospital, Geneva
Conditions:
Chronic Subdural Hematomas
Cerebral Compression Due to Injury
Eligibility:
All Genders
18-100 years
Phase:
NA
Brief Summary
Chronic Subdural Hematomas (cSHD) are common, and due to cerebral compression, often result in neurological impairment and reduced consciousness. Surgery is typically performed once neurological sympt...
Detailed Description
Evidence to support the benefit of MMA embolization remains limited and the risk-benefit balance remains unclear. Case series have shown that recurrence rates with embolization are much lower, and tha...
Eligibility Criteria
Inclusion
- Age: 18-100
- Consent possible
- cSDH located at the convexities
- Patients with symptomatic cSDH
- Patients with asymptomatic large chronic/subacute hematoma after 6 weeks of failed conservative treatment
Exclusion
- Consent not possible
- Pregnancy
- Prisoner
- Angiography contraindication
- Patient for whom follow-up is problematic (e.g. distant residency, homeless …)
- Previous surgery for cSDH
Key Trial Info
Start Date :
February 18 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2027
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT06163547
Start Date
February 18 2025
End Date
January 1 2027
Last Update
March 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Geneva University Hospitals
Geneva, Switzerland